DR. DAVID LYNN VESELY, M.D., PH.D.
Osteopathic Medicine at Bruce B Downs Blvd, Tampa, FL
License number
Florida ME021571
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
License number
Florida C5360
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
13000 Bruce B Downs Blvd, Tampa, FL 33612
Phone
(813) 972-7624
(813) 972-7623 (Fax)
(813) 972-7623 (Fax)
Personal information
See more information about DAVID LYNN VESELY at radaris.comName
Address
Phone
7057 Haviland Cir, Boynton Beach, FL 33437
5056 Ashley Lake Dr, Boynton Beach, FL 33437
5020 Londonderry Dr, Tampa, FL 33647
7057 Haviland Cir, Boynton Beach, FL 33437
5549 Lakeview Mews Ter, Boynton Beach, FL 33437
Professional information
Dr. David L Vesely, Tampa FL - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
13000 Bruce B Downs Blvd SUITE 151, Tampa 33612
(813) 972-7624 (Phone), (813) 972-7623 (Fax)
SCHMIDT, TERRY R DDS
13000 Bruce B Downs Blvd, Tampa 33612
(813) 972-7511 (Phone)
(813) 972-7624 (Phone), (813) 972-7623 (Fax)
SCHMIDT, TERRY R DDS
13000 Bruce B Downs Blvd, Tampa 33612
(813) 972-7511 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 2000, Internal Medicine, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Arizona
Graduated: 1972
University Of Miami Hospitals and Clinics
University of Arizona
Graduated: 1972
University Of Miami Hospitals and Clinics
Chief Of Endocrinology At Department Of Veterans Affairs
Position:
Chief of Endocrinology at Department of Veterans Affairs
Location:
Tampa/St. Petersburg, Florida Area
Industry:
Hospital & Health Care
Work:
Department of Veterans Affairs
-
Chief of Endocrinology
David Lynn Vesely, Tampa FL
Specialties:
Internal Medicine, Endocrinology, Diabetes & Metabolism, Endocrinology and Metabolism, Otolaryngology
Work:
James A. Haley Veterans Medical Center
13000 Bruce B Downs Blvd, Tampa, FL 33612
13000 Bruce B Downs Blvd, Tampa, FL 33612
Education:
University of Arizona (1972) Internal Medicine
Cancer Treatment Using C-Type Natriuretic Peptide
US Patent:
7846900, Dec 7, 2010
Filed:
Dec 30, 2008
Appl. No.:
12/346192
Inventors:
David L. Vesely - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 38/00, C07K 5/00, C07K 7/00
US Classification:
514 12, 514 13, 530324, 530326
Abstract:
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i. e. , the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.
Method Of Treatment Of Cancer Using Guanosine 3', 5' Cyclic Monophosphate (Cyclic Gmp)
US Patent:
2006001, Jan 19, 2006
Filed:
Aug 26, 2005
Appl. No.:
11/162056
Inventors:
David Vesely - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A61K 38/22, A61K 31/7076
US Classification:
514012000, 514047000
Abstract:
A method of treating cancer through use of guanosine 3′,5′-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 μM), 84% (1 mM), 31% (1 μM), and 30% (1 μM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 μM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
Dendroaspis Natriuretic Peptide For Treatment Of Cancer
US Patent:
7825092, Nov 2, 2010
Filed:
Aug 3, 2007
Appl. No.:
11/833757
Inventors:
David L. Vesely - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
United States Department of Veteran Affairs - Washington DC
United States Department of Veteran Affairs - Washington DC
International Classification:
A61K 38/16, A61K 38/17
US Classification:
514 12, 514 2
Abstract:
Disclosed is a method of inhibiting the growth of a cancer cell using Dendroaspis natriuretic peptide (DNP), isolated from the Green Mamba snake venom with similar structure to ANP, with or without four cardiac natriuretic peptides i. e. , atrial natriuretic peptide (ANP), vessel dilator, long acting natriuretic peptide (LANP), and kaliuretic peptide. Dose-response curves revealed a significant (p
Cancer Treatment Using Natriuretic Peptides
US Patent:
8343919, Jan 1, 2013
Filed:
Oct 20, 2010
Appl. No.:
12/908806
Inventors:
David L. Vesely - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
C07K 14/58, A61K 38/00
US Classification:
514 124, 530324, 530326
Abstract:
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i. e. , the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.
Oral Methods Of Treatment Using Proanf Peptides
US Patent:
2006020, Sep 14, 2006
Filed:
Mar 8, 2005
Appl. No.:
11/074063
Inventors:
David Vesely - Tampa FL, US
International Classification:
A61K 38/18
US Classification:
514012000
Abstract:
A method of treatment of hypertension, congestive heart failure, pulmonary edema, nephrotic syndrome, acute and chronic renal failure, toxemia of pregnancy, hepatic cirrhosis, and/or hyperkalemia. Humans or other mammals are administered an effective amount of peptide(s) consisting of amino acids 1-30 (proANF 1-30), amino acids 31-67 (proANF 31-67) and amino acids 79-98 (i.e., proANF 79-98) of the human sequence of the atrial natriuretic factor (ANF) prohormone. Pharmaceutical compositions include such peptides in an effective concentration within a pharmaceutically acceptable liquid or solid carrier given orally.
Dendroaspis Natriuretic Peptide For Treatment Of Cancer
US Patent:
2011003, Feb 10, 2011
Filed:
Oct 20, 2010
Appl. No.:
12/908817
Inventors:
DAVID L. VESELY - Tampa FL, US
Assignee:
UNITED STATES DEPARTMENT OF VETERANS AFFAIRS - Washington DC
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A61K 38/22, C12N 5/071, A61P 35/00
US Classification:
514 124, 435375
Abstract:
Disclosed is a method of inhibiting the growth of a cancer cell using natriuretic peptide (DNP), isolated from the Green Mamba snake venom with similar structure to ANP, with or without four cardiac natriuretic peptides i.e., atrial natriuretic peptide (ANP), vessel dilator, long acting natriuretic peptide (LANP), and kaliuretic peptide. Dose-response curves revealed a significant (p
Urodilatin Cancer Treatment
US Patent:
2009006, Mar 5, 2009
Filed:
Nov 5, 2008
Appl. No.:
12/264997
Inventors:
David L. Vesely - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
UNITED STATES DEPARTMENT OF VETERANS AFFAIRS - Washington DC
UNITED STATES DEPARTMENT OF VETERANS AFFAIRS - Washington DC
International Classification:
A61K 38/22, A61P 35/00
US Classification:
514 12
Abstract:
Urodilatin, a peptide formed in the kidney, has significant anticancer effects eliminating two-thirds of cancer cells within 24 hours.